Familial ovarian dysgerminomas (Swyer syndrome) in females associated with 46 XY-karyotype.
An asymptomatic woman (age 38 years) with a family history of ovarian malignancies was referred for presymptomatic genetic testing of mutations in the BRCA genes. A familial Swyer syndrome with the occurrence of dysgerminomas is the most likely diagnosis. However, in our case, all known causes of this heterogeneous disorder have been excluded pointing to the existence of another yet unknown genetic locus. The family history revealed three affected paternal aunts. Two of them developed ovarian malignancies at 13 and 15 years of age, and died at ages 19 and 20. The third aunt, 82 years old, was affected by this disease at the age of 35. She underwent hormonal treatment for 3 years starting at the age of 15 because of primary amenorrhea. Under this treatment she developed nearly complete secondary sexual characteristics. Karyotype analysis revealed a normal male karyotype (46 XY, QFQ). Pelvic ultrasound showed an uterus of normal size, incompatible with an androgen resistance syndrome or a defect in testosterone biosynthesis. We excluded a mutation in the sex-determining region on chromosome Y (SRY) by direct sequencing of the SRY gene. An involvement of the subtelomeric region of chromosome 9p (9p 24.3) recently reported to be involved in XY-sex reversal phenotypes was excluded by molecular testing for loss of heterozygosity as well as fluorescence in situ hybridization studies. Analyses of the DAX1 gene in the dosage sensitive sex reversal locus on chromosome Xp21 by Southern blot analysis showed no duplications.
Kempe
A
A
Department of Obstetrics and Gynecology, University of Bonn Medical Center, Germany.
Engels
H
H
Schubert
R
R
Meindl
A
A
van der Ven
K
K
Plath
H
H
Rhiem
K
K
Schwanitz
G
G
Schmutzler
R K
RK
D019326:17-alpha-Hydroxyprogesterone / Q000097:blood; D000328:Adult; D000735:Androstenedione / Q000097:blood; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics; D041321:Chromosomes, Human, X / Q000235:genetics; D004252:DNA Mutational Analysis; D013196:Dihydrotestosterone / Q000097:blood; D012734:Disorders of Sex Development; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005835:Genitalia / Q000473:pathology; D006061:Gonadal Dysgenesis, 46,XY / Q000097:blood / Q000235:genetics* / Q000473:pathology; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010051:Ovarian Neoplasms / Q000235:genetics; D010375:Pedigree; D010641:Phenotype; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D012016:Reference Values; D017422:Sequence Analysis, DNA; D012730:Sex Chromosomes; D013739:Testosterone / Q000097:blood; D014463:Ultrasonography; D014599:Uterus / Q000000981:diagnostic imaging
D013196:Dihydrotestosterone; D013739:Testosterone; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; D019326:17-alpha-Hydroxyprogesterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone